Mark A. Hull

5.7k total citations · 1 hit paper
111 papers, 4.2k citations indexed

About

Mark A. Hull is a scholar working on Oncology, Pharmacology and Surgery. According to data from OpenAlex, Mark A. Hull has authored 111 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 35 papers in Pharmacology and 32 papers in Surgery. Recurrent topics in Mark A. Hull's work include Inflammatory mediators and NSAID effects (35 papers), Colorectal Cancer Screening and Detection (22 papers) and Cancer, Lipids, and Metabolism (22 papers). Mark A. Hull is often cited by papers focused on Inflammatory mediators and NSAID effects (35 papers), Colorectal Cancer Screening and Detection (22 papers) and Cancer, Lipids, and Metabolism (22 papers). Mark A. Hull collaborates with scholars based in United Kingdom, United States and Italy. Mark A. Hull's co-authors include Gillian Hawcroft, Paul M. Loadman, P. Louise Coletta, Melvyn Smith, Giles J. Toogood, Prashant Kant, Venkataraman Subramanian, Nicholas Burr, Andrea Belluzzi and Milène Volpato and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Mark A. Hull

106 papers receiving 4.1k citations

Hit Papers

A randomised trial of the effect of omega-3 polyunsaturat... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota
    2017 379 citations Henry Watson, Suparna Mitra et al. Gut profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark A. Hull United Kingdom 36 1.3k 1.2k 1.1k 896 829 111 4.2k
Felix Stickel Switzerland 49 1.9k 1.5× 730 0.6× 413 0.4× 960 1.1× 500 0.6× 181 8.4k
Dennis J. Ahnen United States 39 1.5k 1.1× 2.4k 2.1× 794 0.7× 1.5k 1.7× 714 0.9× 108 5.8k
David Bishop‐Bailey United Kingdom 42 3.1k 2.4× 652 0.6× 1.7k 1.5× 703 0.8× 948 1.1× 77 6.4k
Naoki Yoshimi Japan 37 2.0k 1.6× 790 0.7× 494 0.5× 513 0.6× 680 0.8× 213 4.8k
Randall E. Harris United States 35 869 0.7× 1.3k 1.1× 1.8k 1.7× 350 0.4× 1.1k 1.3× 78 4.9k
Ganesan Ramesh United States 37 2.1k 1.6× 693 0.6× 574 0.5× 502 0.6× 375 0.5× 66 6.4k
Concetta Tuccillo Italy 30 1.2k 0.9× 453 0.4× 318 0.3× 667 0.7× 286 0.3× 97 3.8k
Sunao Kawano Japan 39 1.8k 1.4× 1.1k 1.0× 3.3k 3.1× 2.2k 2.4× 1.0k 1.2× 121 7.6k
Gunther Marsche Austria 44 1.7k 1.3× 340 0.3× 483 0.4× 1.4k 1.5× 483 0.6× 142 6.1k
Teake Kooistra Netherlands 40 2.0k 1.6× 472 0.4× 329 0.3× 1.4k 1.5× 587 0.7× 97 6.4k

Countries citing papers authored by Mark A. Hull

Since Specialization
Citations

This map shows the geographic impact of Mark A. Hull's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Hull with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Hull more than expected).

Fields of papers citing papers by Mark A. Hull

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Hull. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Hull. The network helps show where Mark A. Hull may publish in the future.

Co-authorship network of co-authors of Mark A. Hull

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Hull. A scholar is included among the top collaborators of Mark A. Hull based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Hull. Mark A. Hull is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dunneram, Yashvee, Mark A. Hull, Suparna Mitra, et al.. (2025). Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic Studies. Alimentary Pharmacology & Therapeutics. 62(6). 568–584.
2.
3.
Zulyniak, Michael A., et al.. (2024). Plasma n -3 Polyunsaturated Fatty Acid Levels and Colorectal Cancer Risk in the UK Biobank: Evidence of Nonlinearity, as Well as Tumor Site- and Sex-Specificity. Cancer Epidemiology Biomarkers & Prevention. 34(3). 394–404. 1 indexed citations
4.
Downing, Amy, Elizabeth A. Williams, Colin Rees, et al.. (2023). The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E2 synthesis and platelet activation in participants of the seAFOod polyp prevention trial. International Journal of Cancer. 154(5). 873–885. 3 indexed citations
5.
Davies, John R., Mark Harland, Rasha N.M. Saleh, et al.. (2023). Polymorphisms in Cyclooxygenase , Lipoxygenase , and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial. Cancer Prevention Research. 16(11). 621–629. 6 indexed citations
6.
7.
Volpato, Milène, Michele Cummings, Abeer M. Shaaban, et al.. (2020). Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer. SHILAP Revista de lepidopterología. 1(5). 355–371. 6 indexed citations
8.
Hull, Mark A., Kirsty Sprange, Trish Hepburn, et al.. (2019). Eicosapentaenoic acid and/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT. SHILAP Revista de lepidopterología. 6(4). 1–154. 13 indexed citations
9.
Hull, Mark A., Wei Tan, Aisha Shafayat, et al.. (2018). . Newcastle University ePrints (Newcastle Univesity). 79 indexed citations
10.
Watson, Henry, Suparna Mitra, Fiona Croden, et al.. (2017). A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut. 67(11). 1974–1983. 379 indexed citations breakdown →
11.
Cockbain, Andrew J., Milène Volpato, Alessandra Munarini, et al.. (2014). Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Gut. 63(11). 1760–1768. 89 indexed citations
12.
Young, Alastair L., Gillian Hawcroft, Sarah Perry, et al.. (2013). Regional differences in prostaglandin E2 metabolism in human colorectal cancer liver metastases. BMC Cancer. 13(1). 92–92. 7 indexed citations
13.
14.
Kant, Prashant & Mark A. Hull. (2011). Excess body weight and obesity—the link with gastrointestinal and hepatobiliary cancer. Nature Reviews Gastroenterology & Hepatology. 8(4). 224–238. 85 indexed citations
15.
Cuthbert, Richard, Jonathan M. Wilson, Nicholas A. Scott, P. Louise Coletta, & Mark A. Hull. (2009). Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas. European Journal of Cancer. 45(9). 1654–1663. 20 indexed citations
16.
Sainsbury, Anita, et al.. (2006). Increased biomarkers of colorectal carcinogenesis associated with obesity and Roux-en-Y gastric bypass (RYGB).. Cancer Epidemiology and Prevention Biomarkers. 15.
17.
Hull, Mark A.. (2005). Cyclooxygenase-2: How good is it as a target for cancer chemoprevention?. European Journal of Cancer. 41(13). 1854–1863. 58 indexed citations
18.
Gardner, Sarah H., Gillian Hawcroft, & Mark A. Hull. (2004). Effect of nonsteroidal anti-inflammatory drugs on β-catenin protein levels and catenin-related transcription in human colorectal cancer cells. British Journal of Cancer. 91(1). 153–163. 46 indexed citations
19.
20.
Hull, Mark A., Digby J Cullen, N Hudson, & C J Hawkey. (1995). Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration.. Gut. 37(5). 610–612. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Felix Stickel Breakdown of academic impact, for papers by Dennis J. Ahnen Breakdown of academic impact, for papers by David Bishop‐Bailey Breakdown of academic impact, for papers by Naoki Yoshimi Breakdown of academic impact, for papers by Randall E. Harris Breakdown of academic impact, for papers by Ganesan Ramesh Breakdown of academic impact, for papers by Concetta Tuccillo Breakdown of academic impact, for papers by Sunao Kawano Breakdown of academic impact, for papers by Gunther Marsche Breakdown of academic impact, for papers by Teake Kooistra
Rankless by CCL
2026